Other anticancer or experimental therapy; no other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-vascular endothelial growth factor [VEGF]/fetal liver kinase [Flk-] monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment Use of any other experimental medication(s) within days prior to start of the study treatment. Use of any other experimental drug or therapy within days of starting treatment with abatacept Use of any other experimental drug or therapy within days prior to first dose Treatment with an experimental therapy within the last days Participant has used experimental therapy for acute GVHD within weeks of randomization. If unsure of the definition of \experimental\, discussion with one of the protocol chairs is recommended. Concurrent treatment with other experimental treatments for NSCLC while on the study Prior treatment with radium- dichloride or any experimental radiopharmaceutical. Experimental therapies within weeks before first ZW dosing Involved in other experimental protocols (except with permission of the other study PI) Use of experimental drug within weeks of treatment The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is < times the half-life of the previously administered agent(s). Other concurrent experimental therapies Patients may have received treatment of completely resected early stage melanoma, comprising interferon, radiation treatment, or experimental vaccine therapy, and in the metastatic setting patient can have had treatment such as chemotherapy, immunotherapy (except prior treatment with ipilimumab and IL-), and other experimental agent which was completed weeks prior to enrollment Participants who have already received anti-VEGF or experimental antiangiogenic therapy for glioblastoma Use of any other experimental drug or therapy within days of baseline Patients receiving other experimental immunotherapy Receiving another experimental drug within weeks of initiation of conditioning (day -) unless approved by the PI Use of any other experimental drug or therapy within days of baseline. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.) Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities). Anticancer treatment within designated period before enrollment including\r\n* Minor surgical procedure (such as biliary stenting) within days\r\n* Major surgical procedure or radiation treatment within days\r\n* Chemotherapy or experimental drug treatment with published half-life known to be hours within days\r\n* Experimental drug treatment with unpublished or half-life greater than hours within days\r\n* Radiotherapy for measurable lesions delivered in a normal organ-sparing technique within days (except for palliative radiotherapy) Concomitant therapy with any other experimental drug Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities) Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities) Patients must not be scheduled to receive another experimental drug while on this study. Patients must not be scheduled to receive another experimental drug while on this study Washout period of at least days after any approved or experimental tumor directed therapy prior to start of cyclophosphamide and fludarabine Patients who have been treated with any investigational drug within days prior to the first dose of study medication, or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy Prior experimental therapy within days of enrollment Prior experimental therapy within weeks of planned start of this trial Receiving other experimental therapy Patients must not be scheduled to receive another experimental drug while on this study Prior use of experimental agents for prostate cancer Participants must be more than days removed from most recent minor surgical procedure (such as biliary stenting), days from most recent major surgical procedure, days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be hours or less and days removed from last experimental drug treatment with unpublished or half-life greater than hours Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities) Prior experimental therapy within days of planned start of this trial Use of any other experimental drug or therapy within days of baseline Patients who have received experimental agents within weeks of study entry Use of any other experimental drug or therapy =< days prior to registration on this study; NOTE: Patients on low dose prednisone (=< mg) for treatment of conditions other than CLL are eligible Patients who are currently receiving any other experimental agent, must have stopped other experimental agents at least days prior to st study dose Experimental therapy within weeks prior to first dose of study drug treatment on Study Day of Period A Involved in other experimental protocols (except with permission of the other study PI) Use of any other experimental drug or therapy within days of baseline Patients must not be scheduled to receive another experimental drug while on this study Patients who have taken part in an experimental drug study within weeks of initiating study treatment with sonidegib Patients who have taken part in an experimental drug study =< weeks prior to registration For the MF and MDS/MPN-U arms (arms & ), use of any other standard drug (except hydroxyurea, anagrelide, growth factors, Revlimid, clofarabine, etc) or experimental drug or therapy within days of starting study therapy Use of any other experimental drug or therapy within days of study-related drug therapy Patient should not be getting any other experimental therapy for aGvHD Serology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities) Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities) Use of any other experimental drug or therapy within days of baseline Use of any other experimental drug or therapy =< days prior to registration Use of any other experimental drug or therapy within days of baseline. patients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system; Patient is receiving everolimus in combination with an unapproved or experimental treatment Previous cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor. Subjects who received Gliadel wafers will be excluded. Any other experimental treatment on another clinical trial Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities) Concurrent treatment with other experimental drugs or any other systemic anticancer therapy (due to unknown drug-vaccine potential interactions) Subject is receiving or is less than days since ending other experimental drug (no marketing authorization for any indication) weeks from prior experimental drug No other experimental therapy is permitted while on study Receiving another experimental drug within weeks before initiation of conditioning (day -) Patient must have no plans to receive any other experimental therapy while on the protocol treatment; previous experimental therapy must have been completed at least days prior to registration Therapeutic or experimental monoclonal antibodies within day or prior radiation therapy within days of the first dose of study drug. Prior AML or ALL therapy (non-experimental) within days of first dose of ONO- (except those permitted in the protocol) Planned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy; Use of any other experimental drug or therapy within days of baseline Use of any other standard or experimental therapy within days of starting study therapy Prior treatment with another experimental anti-tumor vaccine is permissible No experimental medications within days of study entry Other experimental drugs =< weeks prior to registration Seronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >= mg/day or prednisone >= mg/day), within weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within days of initiation of the study drug treatment; hydroxyurea is permitted up to hours before the first dose of study drug in patients with rapidly-proliferating disease Other concurrent experimental or investigational drugs Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within days of initiation of the study drug treatment No experimental intravesical therapy within weeks of study entry For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after times the half-life of the agent(s). For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after times the half-life of the agent(s). COHORT A: Concomitant therapy with any other experimental drug COHORT B: Concomitant therapy with any other experimental drug Patient is currently participating in other experimental studies that could affect the primary endpoint (e.g. experimental chemotherapy regimen). Experimental medications within the last weeks prior to day Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within weeks or autologous SCT within weeks of initiation of therapy Use of any other experimental drug or therapy within days of baseline Treatment with any known therapeutic or experimental therapy within weeks prior to enrollment, or currently participating in any other interventional clinical study Concomitant use of other anticancer (except for corticosteroids) or experimental agents Have received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within weeks before the first infusion Receipt of an experimental vaccine within months or in the opinion of the Investigator is responding to an experimental vaccine given within months, or has received any previous gene therapy using an integrating vector Concomitant therapy with any other experimental drug Use of any other experimental drug or therapy within days of baseline Use of any other experimental drug or therapy within days of baseline. Subjects on any other systemic therapy for cancer, including any other experimental treatment Any experimental therapy ? days prior to randomization Patient has used any other anti-cancer drug or therapy, including experimental, within days of initiation of lenalidomide treatment (radiation therapy is allowed within days) Use of any other experimental drug or therapy within days of baseline Use of any other experimental drug or therapy other than carfilzomib and pomalidomide within days of treatment start on this protocol Use of any other experimental anti-cancer drug or therapy within days of initiation of the study drug Use of experimental drugs ? days prior to screening Any experimental imaging agent directed at amyloid within weeks Antileukemia or experimental treatment within weeks of study drug (other than hydroxyurea or -mercaptopurine) Use of any experimental immunotherapy. Undergoing stapled anastomosis with the use of an experimental or non-FDA approved stapler. Prior treatment with a licensed or experimental smoothened inhibitor. Pregnant patients may not receive this experimental therapy Another experimental anti-amyloid therapy other than NEOD within years Receiving other experimental therapy Use of any experimental immunotherapy. weeks from prior experimental drug Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within weeks of initiation of the study or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within weeks or autologous SCT within weeks of initiation of therapy Have received experimental therapy within weeks of enrollment Experimental therapy within weeks prior to first dose of study-drug treatment in Cycle Use of any other experimental drug or therapy within days of baseline Use of any other standard or experimental therapy within days of starting study therapy Currently receiving any other experimental therapy or has received any other experimental therapy within the weeks prior to enrollment Treatment with an experimental drug within days of first dose Use of any other experimental drug or therapy within days of baseline Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within days of entry Patients who have taken part in an experimental drug study within weeks of initiating treatment with LDE At least days must have elapsed since any prior experimental therapy Use of any other experimental drug or therapy within days of baseline Use of any other experimental drug or therapy within days prior to randomization Seronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment Experimental therapy within weeks prior to first dose of study drug Patients must be enrolled in a Phase clinical trial and be within weeks of starting the experimental therapy or intervention Subject is receiving or is less than days since ending other experimental device or drug (no marketing authorization for any indication) Use of any other experimental drug or therapy within days of baseline Involved in other experimental protocols except with permission of other PI Experimental immunotherapies: months Involved in other experimental protocols (except with permission of the other study PI) Involved in other experimental protocols (except with permission of the other study PI) Patients participating treatment trials including targeted therapy, experimental therapy or immunotherapy are also eligible Subjects may not be receiving any experimental therapies Treatment with any experimental therapy within days prior to enrollment or current participation in any other interventional clinical study Donors receiving experimental therapy or investigational agents. Experimental therapy within weeks prior to first dose of study drug treatment in Cycle